Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. The present study was designed to test whether altered renovascular reactivity is associated with the increased risk of radiocontrast nephropathy (RCN) in diabetics. We studied 50 patients (24 diabetics, 26 nondiabetics) with chronic renal insufficiency undergoing cardiac catheterization. Patients were randomized to receive either saline, or one of three renal vasodilator/diuretic drugs-dopamine, atrial natriuretic peptide (ANP), or mannitol-by intravenous infusion during cardiac catheterization. Renal blood flow (RBF) was measured by thermodilution at various time points during cardiac catheterization.
previously compared the incidence of RCN in a group of high-risk patients who received mannitol with that of a similar group receiving ANP, and found no difference between them [7] . We have also reported that dopamine, compared with saline, conferred no protection against RCN in a high-risk patient population [12] . In both those studies, patients with diabetes mellitus had a higher incidence of RCN than nondiabetic patients.
The mechanism by which diabetes mellitus predisposes patients to RCN is unclear. Diabetes mellitus appears to be associated with abnormal resting renal hemodynamics [16] , and exaggerated renal vasodilation with stimulation [17, 18] . One study in diabetic rats implicated altered renovascular reactivity in the pathogenesis of RCN [19] . This relationship has not yet been investigated systematically in human subjects.
We designed the present study to answer two questions: (1) Do patients with chronic renal failure with and without diabetes mellitus differ in their renal hemodynamic response to contrast medium infusion alone or in the presence of experimental renal vasodilator/diuretic drugs? and, if so, (2) Is there a relationship between those immediate renal hemodynamic alterations and the subsequent development of RCN? We found that the experimental drugs were associated with abnormal renovascular reactivity in patients with diabetes mellitus which, in turn, was associated with an increased risk of RCN. These same drugs significantly reduced the risk of RCN among the nondiabetic patients.
Methods

Patient selection
The patient group in the present study has been described in part in previous reports [7, 12, 20] . All patients with chronic renal failure, defined as a stable plasma creatinine concentration (ncr) greater than or equal to 1.8 mg/dl, undergoing elective cardiac catheterization, were considered eligible for inclusion in the study. Patients were excluded if they had New York Heart Association Class IV congestive heart failure, evidence of liver dysfunction, hemodynamic instability, allergy to contrast medium, prior exposure to contrast medium within seven days of the experimental protocol, or were pregnant. Before enrollment in the study, all patients gave written informed consent to 259 participate in the research protocol approved by the Institutional Review Committee at Cooper Hospital/University Medical Center. A medical history was taken and a physical examination performed with attention to the exclusion criteria, current medications, the cause of the chronic renal failure, and underlying illnesses.
Experimental protocol All patients received an intravenous infusion of 0.45% sodium chloride at 100 mllhr beginning 12 hours before, and continuing throughout the cardiac catheterization. Patients were randomly assigned in a double-blind fashion to receive either saline or one of three experimental drugs by intravenous infusion. The infusions began immediately after full instrumentation for the cardiac catheterization procedure and continued for a total of two hours (about twice the duration of the catheterization procedure itself). We randomized the patients in two separate sets: saline (Group 1) versus dopamine (Group 2), and ANP (Group 3) versus mannitol (Group 4). Specifically, Group 1 received 0.45% sodium chloride at 100 milhr, Group 2, dopamine at 2 j.tg/kg/min in 0.45% sodium chloride at 100 ml/hr, Group 3, ANP (Merck, Sharp and Dohme, Rahway, New Jersey, USA), 50 g bolus, followed by an infusion of 1 pg/min in 0,45% sodium chloride at 100 ml/hr, and Group 4, mannitol, 15 g/dl in 0.45% sodium chloride at 100 ml/hr.
Cardiac catheterization was performed by the percutaneous femoral approach. One arterial and two venous sheaths were placed (time 0, t = 0). A Swan-Ganz catheter was placed with its tip in the pulmonary artery for measurement of right heart pressures. A catheter was advanced into the left renal vein for serial measurements of RBF (see below). A pigtail catheter was advanced into the left ventricle for ventriculography. All patients underwent a single ventriculogram, completed by 15 minutes into the catheterization (t = 15),followed by coronary angiography, completed by 65 minutes (t = 65). The contrast medium used in all cases was MD76 (66% diatrizoate meglumine, 10% diatrizoate sodium), an ionic high-osmolality medium. A record was made of total fluid intake and output during the 24 hour period after cardiac catheterization.
Measurement of renal hemodynamics RBF was measured using a 7-French dual-thermistor thermodilution catheter (Webster Labs, Baldwin Park, California, USA), as described in detail previously [7, 12, 20, 21] . In brief, the catheter was passed through the femoral vein sheath and fluoroscopically guided into the left renal vein without the use of contrast medium. To determine RBF, we used a continuous thermodilution technique, injecting room-temperature 5% dextrose through the catheter with a Harvard pump (Harvard Apparatus Co, Millis, Massachusetts, USA) at 50 mI/mm until the temperature deflections recorded from the internal and external thermistors were stable. Three or four replicate RBF measurements were made at approximately one-minute intervals at each time point. RBF was measured at t = 0 (baseline), t = 5 (after the drug infusion was begun but before the Laboratory measurements A blood specimen for P was obtained upon entry into the study. 1Cr measurement was repeated at t = 0(baseline), 24 and 48 hours after the catheterization, and daily thereafter until it returned to the baseline level or stabilized. PCr was determined by a modified Jaffe end-point assay in a Hitachi 737 autoanalyzer (Boehringer-Manheim, Indianapolis, Indiana, USA). We defined RCN as a rise in PCr of at least 25% over baseline by 48 hours after the catheterization. Creatinine clearance (Car) was estimated by the formula of Cockcroft and Gault [221 for all patients, and measured using a 12-hour urine collection for the first 18 patients enrolled in the study.
Statistical analysis
All continuous data were tabulated and analyzed as mean SEM. Paired t-tests or independent t-tests were used to determine differences within or between groups and subgroups, respectively. Differences between proportions were assessed using Chi-squared analysis or Fisher exact test, as appropriate. Linear regression analysis and one-way analysis of variance for repeated measures were performed according to standard procedures. Differences were considered significant at P < 0.05.
Results
Patient characteristics
Fifty patients met the criteria for enrollment in the study and completed the described protocol. Table 1 summarizes their baseline characteristics, according to experimental group and the presence or absence of diabetes mellitus. The mean baseline 'Cr of the population as a whole was 2.5 0.1 mg/dl and was similar in all groups. Within each group, PCr was similar in patients with diabetes mellitus and those without, with the exception of Group 1, in which the mean P,,, was significantly higher in patients with diabetes mellitus. The mean estimated CCr of the study population was 33 2 ml!min. There was a strong correlation between the estimated and measured Ccr (r = 0.84, P <0.0001). Cr was similar in all drug groups. Seventy percent of all the patients (diabetics, 75%; nondiabetics, 65%) were taking calcium channel blockers on a longterm basis at the time of the cardiac catheterization. The mean dose of contrast medium injected during the protocol was 124 6 ml and was similar in all groups, with the exception of Group 3 (ANP), in which the mean dose was lower compared with that in Group 1 (saline) (99 9 ml vs. 140 10 ml, P < 0.05). There were no significant differences in the dose of contrast medium between the diabetic and nondiabetic patients in any group or in the total population.
Renal hemodynamics Mean baseline RBF was consistently lower in patients with diabetes mellitus than in nondiabetics in every group, and this difference achieved statistical significance in Group 2, in all experimental drug groups combined (Groups 2 to 4), and in all groups combined (Groups 1 to 4) ( Table 1) . Likewise, baseline renovascular resistance was higher in diabetics than nondiabetics in each drug group, and this difference was statistically significant for the population as a whole (91,039 17,258 vs. 40,774 5181, diabetics vs. nondiabetics, P < 0.01). Filtration fraction was higher in patients with diabetes mellitus than in nondiabetics (36 5% vs. 24 3%, P <0.05).
RBF rose, and renovascular resistance fell, in the population as a whole over the course of the cardiac catheterization (P < 0.01). These renal hemodynamic changes were accounted for largely by the behavior of the diabetic subpopulation, in which there was a significant increase in RBF, and decline in renovascular resistance, over time (P < 0.01), and at every time point (P < 0.05 vs. t = 0). Among the nondiabetic patients, there was a significant increase in RBF at t = 15 and t = 65 (129 13%, 132 10%, respectively, P < 0.05 vs. t = 0), but these increases were significantly smaller than those of the diabetic subpopulation at each time point (P < 0.05; Fig. 1 ).
Time, minutes In Group I (saline control) as a whole, RBF rose significantly over time (P < 0.01) and again, the increase among the patients with diabetes mellitus was explanatory: RBF rose over time only among the diabetics (P < 0.05); in the nondiabetic subgroup, there was a significant increase in RBF at t 65 only (Fig. 2 ).
RBF rose significantly over time only among the diabetic patients in Group 2 (dopamine), Group 3 (ANP) and Group 4 (mannitol) (all P < 0.05). In Group 2, the increase in RBF in the diabetic subgroup was greater than that of the nondiabetic subgroup at each time point (P < 0.05).
When results from all the experimental drug groups (Groups 2 to 4) were combined, RBF rose significantly over time (P < 0.01). This rise, however, was due almost entirely to the change in RBF in the diabetic subgroup (P < 0.01); there was no change in RBF over time in the nondiabetic subgroup. At each time point, the diabetic subgroup showed a significant increase in RBF, compared to baseline (P < 0.05), which was greater than that of the nondiabetic subgroup (P < 0.05; Fig. 2) .
After five minutes of drug infusion and immediately before the first injection of contrast medium (t = 5), RBF had risen significantly among only the diabetic patients in Groups 2 to 4 combined (210 37% and 112 13% baseline RBF, for diabetics and nondiabetics, respectively; P < 0.05 vs. baseline RBF for diabetics only). In the saline control group at t = 5, however, RBF had not changed significantly in either diabetics or nondiabetics (110 14% and 110 23%, respectively). There were no differences in baseline RBF or the change in RBF at t = 5, t = 15 or t = 65 between patients taking or not taking calcium channel blockers on a long-term basis. The increase in RBF at t = 65 correlated inversely with the baseline RBF (r = -0.39, P < 0.01). This relationship was explained completely by the behavior of the diabetic subpopulation (r = -0.54, P < 0.01). There was no relationship between baseline RBF and a change in RBF at t 65 among nondiabetics. The P 48 hours after the catheterization, expressed as a percentage of the baseline PCr, rose in the population as a whole (118 5% baseline PCr' P < 0.05 vs. baseline), and that rise was inversely proportional to the baseline RBF (r = -0.33, P < 0.05). The increase in PCr in the population as a whole, however, was due entirely to the rise in PCr among patients with diabetes mellitus (diabetics 138 7% vs. nondiabetics 99 3%; P < 0.05). When analyzed by individual drug group, the change in Cr was significantly greater in diabetics than nondiabetics for each group except the saline control (Fig. 3) . Table 2 shows the incidence of RCN by group, and according to the presence or absence of diabetes mellitus. Overall, 19 of 50 patients (38%) developed RCN. The overall incidence of RCN was similar in Groups 1 to 4.
When patients with and without diabetes mellitus were analyzed separately, however, striking differences were seen in the incidence of RCN with the various drug protocols. and 75% of the diabetics in these groups, respectively, developed RCN. Within each of these groups, the difference in the incidence of RCN between diabetics and nondiabetics was significant (P < 0.05, Fisher exact test). In the saline control group, however, there was no difference between diabetics and nondiabetics with respect to the incidence of RCN. Among nondiabetics, the incidence of RCN was significantly lower in Groups 2 to 4 combined, than in Group 1 (0% vs. 38%, P <0.05, Fisher exact test). Among diabetics who received one of the experimental drugs, however, the incidence of RCN tended to be higher than among those who received saline (81% vs. 43%), although the difference was not statistically significant.
The incidence of RCN was not significantly different in the presence or absence of long-term calcium channel blocker therapy (41% and 27%, respectively; P 0.52, Chi-squared).
Fluid balance Forty-one of the 50 patients had complete records made of fluid intake and output during the 24 hours following cardiac catheterization. Of the nine patients without data collected, five were diabetic, five received saline, two ANP, one mannitol and one dopamine. Two developed RCN, both of whom were diabetics who had received ANP. Table 3 shows the mean fluid balance during the first 24 hours after cardiac catheterization for patients by drug group and according to the presence and absence of diabetes mellitus. Net fluid balance was positive for all groups except the nondiabetics who received ANP, and was the same in diabetics and nondiabetics (732 312 ml vs. 961 249 ml, respectively; NS). For the population as a whole, the greater the increase in PCr at 48 hours, the more positive the net fluid balance (r = 0.37, P < 0.05). That same relationship held for nondiabetics (r 0.51, P <0.05), but not for diabetics, in whom there was no significant relationship between fluid balance and change in Cr Among Table 3 . Fluid balance (ml) at 24 hours Table 2 . Incidence of RCN by drug group, diabetics and nondiabetics patients with positive net fluid balance, the risk of RCN was higher in diabetics than nondiabetics in the population as a whole (P < 0.05), and in patients receiving dopamine, ANP and mannitol (P < 0.01). Four patients had a net fluid loss of more than 500 ml in the 24 hours after cardiac catheterization. Two of those patients, both diabetic, developed acute renal failure, one of whom had received saline and the other ANP.
Discussion
Previous studies have shown that diabetes mellitus increases the risk of RCN [1] [2] [3] [4] . The results of the present study corroborate those observations. The incidence of RCN was significantly higher in the patients with diabetes mellitus than in those without, and patients with diabetes mellitus had approximately six times the risk of RCN as nondiabetics.
Paradoxically, the incidence of RCN was highest among the diabetic patients who received the vasodilator/diuretic drugs postulated to prevent RCN: dopamine, ANP and mannitol.
Among the diabetic patients, the incidence of RCN was higher in all the experimental drug groups than in the saline control group, although that difference did not achieve statistical significance. In each of the vasodilator/diuretic drug groups, the incidence of RCN was significantly higher in patients with diabetes mellitus than in those without. In the saline control group, however, there was no difference between diabetic and nondiabetic patients with respect to the incidence of RCN.
These findings strongly implicate the experimental drugs used in the present study in the increased risk of diabetic patients for RCN. Prerenal azotemia cannot explain the rise in Cr' since the mean net fluid balance was positive for all groups in which acute renal failure developed, and since only two of the nineteen patients who developed acute renal failure were documented to have had a significant net fluid loss during the post-catheterization period.
Because of those observations, and because of the prominent role given to immediate renal hemodynamic changes in the proposed pathogenesis of RCN [8, 9] , we sought to explain the different risks of diabetic and nondiabetic patients by examining the change in RBF during exposure to contrast medium. We found that the rise in RBF throughout the cardiac catheterization in the population as a whole was mainly due to the change in RBF in the diabetic subpopulation (Fig. 1 ). This disparity in the renal hemodynamic responses of the diabetics and nondiabetics in the population as a whole was explained, in turn, by the behavior of the patients receiving the experimental drugs (Groups 2 to 4). Only the diabetic patients showed a significant increase in RBF over time. In the saline control group, however, the responses of the diabetics and nondiabetics were not nearly as disparate as they were in the experimental groups (Fig. 2 ).
The patients with diabetes mellitus in our study had significantly lower RBF at baseline than the nondiabetic patients, despite comparable Car. This renal hemodynamic profile, and the resulting elevation in filtration fraction, have been described previously in type I diabetes, both early [16] and advanced [21, 23, 24] , and in early type II diabetes [21, 25, 26] . The present study suggests that these renal hemodynamic characteristics may also be implicated in the predisposition of diabetic patients to RCN. The baseline RBF was inversely proportional to both the increase in RBF at the end of the cardiac catheterization and to the rise in PCr after exposure to contrast medium in the patients with diabetes mellitus only. Thus, the baseline renal vasoconstriction and/or the renal vasodilation during the procedure appears to have predisposed the diabetic patients to RCN.
The results of the present study do not explain why the unique renal hemodynamic characteristics of the patients with diabetes mellitus should have predisposed them to RCN. It is interesting to speculate about the role of medullary oxygen economy in this regard. While contrast medium administration does not appear to be associated with a reduction in global RBF in humans [20] , there is evidence from studies of rats that it may cause a redistribution of blood flow from the medulla to the cortex [27] . Such a reduction in medullary blood flow would result in a decrease in oxygen delivery to a region of the kidney with very low oxygen tension under even basal conditions. Indeed, RCN in the rat is manifested by ischemic damage of the medullary thick ascending limb of Henle's loop [28] .
How might the marked increase in global RBF experienced by the diabetic patients in the present study be associated with an exacerbation of medullary ischemia? Some light is shed on this question by a recent study in rats [29] showing an association between renal vasodilation induced by glycine infusion during contrast medium exposure and an increase in outer medullary damage. In that study, the increase in RBF was accompanied by a sharp decrease in medullary oxygen tension, perhaps partly due to shunting of blood away from that region. Similarly, medullary hypoxia may have developed with the experimental drugs used in our study for at least two reasons. First, it is possible that the increase in global renal blood flow seen in the present study was accompanied by an intrarenal redistribution of blood flow, reducing medullary oxygen delivery and enhancing susceptibility to ischemic injury with contrast medium exposure [27] [28] [29] [30] . Diabetic animals [31] [32] [33] and humans [34] appear to have deficient endothelium-dependent vasodilation, that is, a lack of, or insensitivity to, endotheliumderived relaxing factor (EDRF). That would explain the basal renal vasoconstriction seen in our diabetic patients and their exaggerated renal vasodilation with dopamine, ANP and mannitol, all of which have endothelium-independent vasodilatory action. (Such effects were seen with ANP administration to rats made EDRF-deficient [35] ). If such exaggerated renal vasodilation were predominantly cortical (as appears to be the case with dopamine administration [36] ), a medullary "steal" might ensue with subsequent contrast medium infusion. Supporting a critical role for medullary oxygen delivery in the pathogenesis of RCN is the observation that inhibiting EDRF synthesis reduces renal medullary oxygen tension and exacerbates contrast medium-associated damage in rats [37] .
Second, oxygen demand may have risen due to increased distal solute delivery accompanying the use of the experimental drugs, all of which would increase solute delivery to the medulla by blocking proximal sodium reabsorption and/or increasing glomerular filtration rate.
The combination of these two factors would clearly work together to reduce the oxygen supply:demand ratio, predisposing to ischemic injury. In addition, the kidneys of diabetic patients may be more susceptible to ischemia at a given level of solute delivery than those of nondiabetics [19] .
In contrast to the diabetic patients, the nondiabetic subpopulation was significantly protected from RCN by the experimental drugs used in the present study. Indeed, the incidence of RCN among nondiabetics in all the experimental drug groups was zero. Commonly accepted formulations of the pathogenesis of RCN [8, 9] would lead to the conclusion that the protective effect was due to preservation of global renal blood flow during contrast medium exposure. Figure 2 , however, shows that RBF of nondiabetic patients who received the experimental drugs was no different from that of nondiabetic patients in the saline control group, while the incidence of RCN was significantly higher in the latter group. The protection may be due to the increased tubular flow rate and, thus, a reduction in the concentration of contrast medium to which the kidney is exposed. Such an explanation is purely speculative, however. The mechanism whereby these drugs protect nondiabetic patients with chronic renal insufficiency from RCN is not evident based on the results of the present study.
In summary, the higher risk of diabetic patients for RCN was related to their exaggerated renovascular reactivity, expressed both as renal vasoconstriction at baseline, and as renal vasodilation during contrast medium exposure in the presence of renal vasodilator/diuretic drugs. In contrast, the nondiabetic patients in our study were significantly protected from RCN by the experimental drugs, without any attributable increase in global renal blood flow. Thus, the experimental drugs used in the present study (dopamine, ANP and mannitol) reduced the incidence of RCN in nondiabetics and tended to increase the incidence in diabetics, probably through different mechanisms. Our study supports the use of ANP, mannitol or dopamine to prevent RCN only in patients without diabetes mellitus. The data further suggest that those same drugs, two of which are commonly used during contrast medium infusion, may be harmful in diabetic patients.
